Pain and Stress Assessment and ROP Screening

December 13, 2018 updated by: Danilyn Angeles, PhD, Loma Linda University

Pain and Stress Assessment and ROP Screening Examination in Premature Infants

The study will measure the effects of eye exams on markers of stress in the urine. In addition, measurements will be taken to show the effects of stress on brain activity, O2 sats, and blood flow.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

42

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Loma Linda, California, United States, 92354
        • Loma Linda University Children's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 months to 7 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Premature infants undergoing SOC ROP eye exams

Description

Inclusion Criteria:

  • Premature infants between 24 -32 weeks of gestational age

Exclusion Criteria:

  • Infants scheduled for laser eye surgery on the day of the examination
  • Infants with intraventricular hemorrhage ≥ grade 3 (Papile classification) diagnosed by head ultrasound
  • Infants receiving the following medications: morphine, fentanyl, methadone, midazolam, lorazepam, muscle relaxants, phenobarbital, phenytoin, levetiracetam
  • Renal injury defined with plasma creatinine > 1.5 mg/dL
  • Severe cyanotic congenital heart disease
  • Unstable respiratory distress (hypoxemia PaO2 < 50 mm Hg or SpO2 < 90%)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Urine Stress Marker
Time Frame: 24 hours
Collection to occur 3-4 hours before eye exam and 24 hours after the eye exam.
24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
aEEG
Time Frame: 24 hours
1 hour prior to the eye examination and will remain there until 24 hours after the end of the eye exam.
24 hours
NIRS
Time Frame: 24 hours
1 hour prior to the eye exam and will be kept in place until 24 hours after the end of the eye exam
24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Andrew Hopper, MD, Loma Linda University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2015

Primary Completion (Actual)

December 1, 2018

Study Completion (Actual)

December 1, 2018

Study Registration Dates

First Submitted

April 9, 2015

First Submitted That Met QC Criteria

April 13, 2015

First Posted (Estimate)

April 14, 2015

Study Record Updates

Last Update Posted (Actual)

December 17, 2018

Last Update Submitted That Met QC Criteria

December 13, 2018

Last Verified

December 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • 5150005

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain

Subscribe